Stockholm, Sweden, January 26, 2024 (NYSE: ALV and SSE: ALIV.sdb) Q4 2023: Record sales and strong profitability
All the statistics in this report are provided on a comparable basis.Settlement PBOC e-CNY Interest Rates Previous : PBOC:Report on Aggregate Financing to the Real Economy (Stock) (October 2023) Next : Two int'l e-commerce standards released in China's Hangzhou ...
October 24, 2023 Q3 2023 Financial Report [PDF - 0.46 MB] Q3 2023 Financial Report Conference Call Slides [PDF - 3.17 MB] Q3 2023 Financial Report Conference Call Audio [MP3 - 49.62 MB] Q3 2023 Financial Report Conference Call Transcript [PDF - 0.25 MB] ...
On the evening of April 29, NavInfo released its full-year financial report for 2023. The financial report shows that the company’s total operating income last year was 3.122 billion yuan. The operating income of the fully developed smart driving business was 376 million yuan, a year-on-yea...
Interim report January–September 2023: October 26, 2023 Annual Report 2022 The Annual Report 2022, including Financial Statements and the Report by the Board of Directors, will be published on the Group’s website during week 8. Annual General Meeting ...
I present my report for the financial year ended 30 June 2023, together with our perspective on the best way forward for the Company. The financial year can be separated into two distinct periods. During the first six months, Macau was subject to strict dynamic zero-COVID regulations, in lo...
Leiden, The Netherlands, October 12, 2023: Pharming Group N.V. confirms it will report its preliminary third quarter 2023 financial results, for the period ended September 30, on Thursday, October 26, 2023. Leiden, The Netherlands, October 12, 2023:(“Pharming”) (Euronext ...
Holding Company Reorganization– On October 2, 2023, NorthWestern Corporation (NW Corp) and NorthWestern Energy Group completed a merger transaction pursuant to which NorthWestern Energy Group became the holding company parent of NW Corp. In this reorganization, shareholders of NW Corp (the predecessor...
argenx to report topline data from the registrational Phase 3 ADDRESS trial of efgartigimod SC in pemphigus around year-end 2023. We are participating in the study inGreater China. argenx to file the supplemental BLA in CIDP by the end of 2023. ...
Q3 2023 – Transcript (26 October 2023, PDF) Q32023 – Pillar 3 (3 November 2023, PDF) Q2 (Half year) Half Year – Interim Report (28 July 2023, PDF) Half Year – Presentation (28 July 2023, PDF) Half Year – Data Pack (28 July 2023, Excel) ...